Trusted Resource for Clinical Trials, Protocols & Progress
Prior to CTR 536/2014, the EU clinical trial landscape operated under Directive 2001/20/EC. However, this directive allowed each Member State to transpose the law into national legislation individually, resulting in inconsistencies, duplicated efforts, and delays—particularly in multi-country trials.
Click to read the full article.
Despite CTR’s harmonization, sponsors must consider language requirements, Ethics Committee processes, and local nuances in some Member States. The EMA encourages sponsors to consult national regulatory portals in parallel and to designate an EU legal representative when the sponsor is based outside the EU/EEA.
Click to read the full article.
Sponsors conducting multinational trials must align document versions and manage translations carefully for Part II submissions. Also, legal representatives are required for non-EU sponsors to access CTIS and conduct regulatory interactions. Ethics Committees still operate under national law, but their assessments are logged within the CTIS framework.
Click to read the full article.
While GDPR is directly applicable across the EU, individual Member States can have additional rules on the use of personal data for health research. For example, France requires specific approvals from CNIL, while Germany’s states may impose layered requirements. Sponsors conducting multi-country trials must assess local data protection nuances.
Click to read the full article.
Trial sponsors conducting multi-country trials must assess variations in:
Language requirements for patient materials
Legal capacity and surrogate consent regulations
Regional sensitivities regarding trial populations (e.g., minors, terminally ill)
Multi-country trials involving pediatric populations, rare diseases, or advanced therapies (e.g., ATMPs) require careful coordination of additional regulatory layers. Sponsors must also be mindful of:
Data privacy requirements under GDPR
Local pharmacovigilance obligations during development
Informed consent models accepted in each country
Pediatric studies in rare diseases, oncology, and gene therapy require:
Additional ethical and scientific review layers
Flexible trial designs and extrapolation techniques
Access to pediatric expert networks and advocacy input
RBM implementation varies depending on:
Therapeutic area (oncology trials often need more intensive monitoring)
Trial phase (Phase I vs. Phase III)
Site maturity and historical performance
Use of decentralized elements (telemedicine, eConsent)
Transparency is especially critical in:
Pediatric trials, where early disclosure informs treatment guidelines.
Rare disease trials, where data sharing accelerates research progress.
COVID-19 vaccine trials, which highlighted the importance of timely public access to trial data.
Sponsors must pay extra attention when conducting trials in:
Rare diseases, where small batch supplies increase the risk of shortages.
Oncology, where comparators may be expensive and difficult to source.
Advanced therapies (ATMPs), where supply involves personalized manufacturing and just-in-time logistics.
